Stryker Corporation SYK
Verdict: Hold. Fair value $332 against a price of $367 on 6 Jan 2026, 10% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins.
Main risks
- Declining Annual Net Income: Net income fell from $3.17B in 2023 to $2.99B in 2024 despite a 10.2% increase in revenue, indicating significant net margin compression.
- Elevated Leverage: The estimated Total Debt to EBITDA ratio is ~2.8x, which is on the higher side and warrants monitoring, especially without visibility into cash balances or interest coverage.
- Divergence between FCF and Net Income: TTM FCF ($4.07B) is significantly higher than the latest annual Net Income ($2.99B), which could be due to favorable working capital changes but requires deeper investigation to ensure earnings quality.
- Intense competitive environment
- Valuation prices in optimistic scenario (limited margin for error)